Neurotrophic Tyrosine Receptor Kinase Fusion (NTRK)

Episode
96
Soundcloud
Share

Neurotrophic tyrosine receptor kinase fusion, or NTRK, has emerged in the last six years as a rare, but targetable alteration in several cancers. Dr. Herbert Loong, clinical assistant professor in the department of clinical oncology and deputy medical director of the Phase 1 Clinical Trials Center of The Chinese University of Hong Kong, joins Lung Cancer Considered host Dr. Stephen Liu to discuss NTRK and what impact it may have on lung cancer research and treatment.

Guest
Stephen Liu, MD
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Herbert Loong
Herbert H. Loong
Associate Professor
Department of Clinical Oncology Deputy Medical Director – Phase 1 Clinical Trials Centre

Other Podcast

Lung Cancer Considered Episode 107 International Medical Graduates with Dr. Marina Chiara Garassino & Dr. Suresh Ramalingam
Episode
107
Lung Cancer Considered: ASCO Highlights 2022 with Jack West & Catherine Shu
Episode
106
Lung Cancer Considered ADC Podcast with Drs. Ben Levy and Rebecca Heist
Episode
105